CompletedNot Applicable

Ultra-low Dose Contrast for Endovascular Procedures

Greece18 participantsStarted 2024-09-01

Plain-language summary

The purpose of this protocol is to study the safety and feasibility of using ultra-low dose iodinated contrast agent for infrainguinal endovascular revascularization procedures in patients with chronic limb-threatening lower limb ischemia (CLTI) and impaired renal function, in the new angiography suite of our department.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * CLTI * Prescheduled infrainguinal revascularization procedure * Renal disease stage 2-4 (eGFR \<60ml/minute/1.73m2) * Adequate pre- and post-procedural hydration protocol Exclusion Criteria: * Inadequate pre- and post-procedural hydration protocol * End-stage renal disease/ dialysis * eGFR \>60ml/minute/1.73m2) * Endovascular treatment of Iliac artery steno-oclussive disease * Allergy to contrast media

What they're measuring

Renal function

Timeframe: From the end of the procedure to day 2

Technical success

Timeframe: Day 1

Trial details

NCT IDNCT06835127

SponsorAttikon Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-01-23

View on ClinicalTrials.gov More Renal Impairment trials